Jagsonpal Pharmaceuticals Limited — Updates, 22-01-2025: Press Release

Jagsonpal Pharmaceuticals Limited has reported strong financial results for Q3 FY25 and the nine months ending December 31, 2024. Revenue for Q3 FY25 reached ₹740 million, representing a significant 57% growth compared to Q3 FY24, while the nine-month revenue surged by 27% to ₹2,102 million. Operating EBITDA for Q3 soared to ₹171 million, translating to a healthy margin of 23.1%, up from 12.8% in the same quarter last year. The company also recorded a growth of 67% in business PAT, which reached ₹115 million for Q3 and ₹316 million for the nine months.

Key highlights include the strategic sale of the Faridabad facility for ₹410 million, substantially enhancing the cash position to ₹1,321 million, thereby ensuring financial flexibility for future investments. The successful integration of the acquired business from Yash Pharma is anticipated to contribute positively going forward, supporting Jagsonpal's ongoing focus on both organic and inorganic growth. With a robust balance sheet and strong operational momentum, the company is well-positioned for future opportunities.